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ABSTRACT
Objectives: Pseudomonas aeruginosa is an opportunistic pathogen that has an innate resistance to some antibiotics. This bacterium is one of the most 
common causes of nosocomial infections that include surgical wound infections, burns, and urinary tract infections. The bacteria have been reportedly 
resistant to many antibiotics and have developed multidrug resistance (MDR). The objective of the study was to determine the resistance pattern of 
P. aeruginosa isolated from clinical samples of patients against some major antibiotics.
Methods: Isolates of P. aeruginosa were obtained from clinical sample of urine, sputum, swabs, pus, feces, and blood and cultured in cetrimide agar. P. 
aeruginosa ATCC 27853 was used as a positive control. The antibacterial susceptibility testing was conducted against 13 antibiotics: Ceftazidime, cefotaxime, 
ceftriaxone, cefoperazone, ciprofloxacin, levofloxacin, ofloxacin, gentamicin, amikacin, piperacillin, ticarcillin, meropenem, and imipenem. The examination 
was carried out using agar diffusion method of Kirby-Bauer and following the standards from Clinical and Laboratory Standards Institute (CLSI).
Results: The results showed that bacterial resistance was established against all tested antibiotics. The highest number of resistance was shown 
against ceftriaxone (44.21%), whereas the most susceptibility was exhibited against amikacin (only 9.47% of resistance). MDR P. aeruginosa (MDRPA) 
was detected on almost all clinical samples tested, except the feces. The sample with the highest percentage of MDRPA was the pus.
Conclusion: The study concludes that the most effective antibiotic against P. aeruginosa is amikacin (91.51%), whereas the most resistance is 
exhibited to ceftriaxone (43.16%).
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogenic bacterium 
that is well known as an important cause of nosocomial infections [1]. 
The incidence of nosocomial infections in the world which are caused 
by P. aeruginosa is approximately 10-15% and 10-20% in the Intensive 
Care Unit, usually occurs in patients with septicemia, cystic fibrosis, 
burns, and wound infection [2-4]. Successful treatment of infectious 
diseases is determined by rational use of antibiotics, especially the 
efficacy of the drugs. Recently, this bacterium is reported to have 
developed resistance and even multidrug resistance (MDR) against 
antibiotics [5-7]. Some mechanisms of bacterial resistance have been 
recognized and well understood. Bacteria may develop the resistance 
through the production of beta-lactamase enzyme that can destroy 
the antibiotic, changing intracellular targets of antibiotics, and efflux 
pump [8].
MDR P. aeruginosa (MDRPA) is a condition, in which the bacteria are 
resistant to three or more antibiotics [9]. The incidence of MDRPA was 
reported to range from 0.6% to 32%. Its prevalence increased over 
the last decade in hospitalized patients, resulting in fewer choices 
for successful treatment [10]. In a General Hospital in Padang city, 
Indonesia, Pseudomonas sp. has been classified into the MDR bacteria 
with a considerable percentage within 3 years: 88% in 2010, 61% in 
2011, and 66% in 2012 [11].
The objective of this research was to study the pattern of P. aeruginosa 
bacterial resistance isolated from urine, sputum, swabs, pus, feces, 
and blood of hospitalized patients and to determine the percentage of 
P. aeruginosa that exhibits MDR against some popular antibiotics.
MATERIALS AND METHODS
Drugs and bacterial media
Antimicrobial susceptibility discs and bacterial growth media were 
purchased from Oxoid (Thermo Scientific Microbiology Pvt. Ltd.). 
Control sample P. aeruginosa ATCC 27853 was obtained from the 
National Agency of Drug and Food Control, Republic of Indonesia in 
Padang city, West Sumatra.
Samples collection and preparation
Isolate samples of P. aeruginosa were obtained from urine, sputum, 
swabs, pus, feces, and blood of psatsients from a General Hospital in 
Padang, West Sumatra, Indonesia. All samples were cultured in medium 
cetrimide agar. Greenish or yellow-green fluorescence after incubation 
for 24 hrs indicated a positive isolate of the bacterium. All procedures 
and experimental protocols were approved by the Ethical Committee of 
Faculty of Medicine, Andalas University, No: 062/KEP/FK/2015.
Antimicrobial susceptibility testing
The antimicrobial activity of antibiotics was determined using Mueller-
Hinton agar medium. Antimicrobial susceptibility testing of all cultures was 
conducted against 13 different antibiotics: Ceftazidime (30 µg), cefotaxime 
(30 µg), ceftriaxone (30 µg), cefoperazone (30 µg), ciprofloxacin (5 µg), 
levofloxacin (5 µg), ofloxacin (5 µg), gentamicin (10 µg), amikacin (30 µg), 
piperacillin (100 µg), ticarcillin (75 µg), meropenem (10 µg), and imipenem 
(10 µg). P. aeruginosa ATCC 27853 was used as a positive control.
Blocked diameter produced by the antibiotics was compared to the 
standard according to antimicrobial susceptibility testing standard of 
the Clinical and Laboratory Standards Institute (CLSI) [12]. Further 
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test was conducted to explore the susceptibility of the sample cultures 
against each antibiotics. The number of sample cultures was then 
counted based on their susceptibility and classified to sensitive (S), 
intermediates (I), and resistant (R). P. aeruginosa was considered to 
exhibit MDR when the bacterial resistance was developed against three 
or more antibiotics used in the test.
RESULTS
A total of 95 isolates of P. aeruginosa were used in the study. All samples 
were isolated from sputum (35), swab (22), pus (23), urine (10), 
blood (3), and stool (2) of patients. Table 1 shows the diameter of 
clear zone produced by antibiotics when tested to the control culture 
P. aeruginosa ATCC 27853 compared to standard according to CLSI. The 
susceptibility of entire sample cultures against each antibiotic is shown 
in Table 2 and Fig. 1. Meanwhile, the result of susceptibility testing per 
clinical samples is presented in Fig. 2.
The result of bacterial susceptibility testing showed that approximately 
36% of the sample isolates were MDRPA, in which the bacteria were 
resistant to at least three antibiotics. Meanwhile, 18% of the sample 
cultures were also resistant to one to two antibiotics. On the other 
hand, the sensitive bacterial culture to antibiotics was below a half of 
the samples (46%).
DISCUSSION
The antibacterial susceptibility testing in the present study was carried 
out by the agar diffusion method. The diameter measured in this method 
is inhibition of bacterial growth, which appears as a clear zone around 
the disc. This diameter represents the potency of antibacterial activity 
of the drug [13]. This technique is an important method in assessing the 
microbial susceptibility testing that has been used worldwide for more than 
50 years. The result of such technique is considered to show comparable 
result to other methods, such as microdilution technique [14,15].
In the present study, the highest level of resistance of P. aeruginosa was 
shown against ceftriaxone that reached 44% out of 95 bacterial culture 
samples. Some reports also state that this antibiotic has been facing 
an extensive microbial resistance across the globe. The resistance 
rate for this drug in the present study is greater than the result of a 
study in 2012 conducted at three hospitals in South West Nigeria, in 
which 34.5% were resistant to ceftriaxone [16]. Several studies have 
confirmed that Pseudomonas aeruginosa is mostly resistant against 
ceftriaxone [3,17,18]. However, this high level of resistance is not 
quite surprising as some suggest that ceftriaxone has considerably low 
activity against P. aeruginosa [19,20].
High rate of resistance to cephalosporin class (e.g., ceftriaxone) occurs 
because of a mutation that results in the production of Penicillin-
Binding Proteins (PBP). In addition, the resistance may also occur 
because of mutations that altered porin, beta-barrel proteins that cross 
a cellular membrane and act as a pore, that is, involved in the transport 
across the membrane. This alteration causes cephalosporins cannot 
reach the cytoplasmic membrane where the PBP is located. The ability 
of this bacterium to produce lactamase may also increase the resistance 
to antibiotics. This enzyme is known to hydrolyze the lactam ring bond 
resulted in the inactivation of antibiotics [21].
Table 1: Antibacterial activity of antibiotics against control 
Pseudomonas aeruginosa ATCC27853
No. Antibiotic Diameter of inhibition zone (mm)
Sample culture CLSI standard
1 Ceftazidime 22.00 22-29
2 Cefotaxime 20.25 18-22
3 Ceftriaxone 26.00 17-23
4 Cefoperazone 26.00 23-29
5 Ciprofloxacin 38.50 25-33
6 Levofloxacin 36.00 19-26
7 Ofloxacin 32.25 17-21
8 Gentamicin 20.00 16-21
9 Amikacin 24.00 18-26
10 Piperacillin 29.50 25-33
11 Ticarcillin 26.50 21-27
12 Meropenem 40.25 27-33
13 Imipenem 33.68 20-28
CLSI: Clinical and Laboratory Standards Institute
Table 2: Percentage of bacterial susceptibility category of 
Pseudomonas aeruginosa against 13 different antibiotics
No. Antibiotic Bacterial susceptibility (%)
Susceptible Intermediate Resistant 
1 Ceftazidime (CAZ) 65 (68.42) 5 (5.26) 25 (26.32)
2 Cefotaxime (CTX) 20 (21.05) 36 (37.89) 39 (41,05)
3 Ceftriaxone (CRO) 47 (49.47) 6 (6.32) 42 (44.21)
4 Cefoperazone (CFP) 53 (55.79) 6 (6.32) 36 (37.89)
5 Ciprofloxacin (CIP) 67 (70.53) 3 (3.16) 25 (26.32)
6 Levofloxacin (LEV) 66 (69.47) 9 (9.47) 20 (21.05)
7 Ofloxacin (OFX) 62 (65.26) 2 (2.11) 31 (32.63)
8 Gentamicin (CN) 61 (64.21) 5 (5.26) 29 (30.53)
9 Amikacin (AK) 85 (89.47) 1 (1.05) 9 (9.47)
10 Piperacillin (PRL) 77 (81.05) 0 18 (18.95)
11 Ticarcillin (TIC) 69 (72.63) 0 26 (27.37)
12 Meropenem (MEM) 71 (74.74) 1 (1.05) 23 (24.21)
13 Imipenem (IPM) 71 (74.74) 1 (1.05) 23 (24.21)
Fig. 1: Bacterial susceptibility of clinical samples against 
13 different antibiotics (n=95)
Fig. 2: Bacterial susceptibility of different clinical samples 
against antibiotics. Total percentage of sensitive, resistant to ≤2 
antibiotics, and multidrug resistance is 46.32%, 17.89%, and 
35.79%, respectively
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The most sensitive test result in the present study was shown to 
amikacin where 89.47% of the samples were susceptible to this 
antibiotic. This result is very comparable with a study conducted on 
patients in the burns unit at the Menoufia University Hospitals, Egypt, 
in which 89% of the isolates were sensitive to amikacin [22]. A recent 
study from India has also reported a good efficacy of amikacin against 
P. aeruginosa, with <6% of unsusceptibility, placing the drug as the most 
effective one to kill the bacteria among others tested [4]. However, the 
efficacy of this drug is reportedly lower when tested to samples from 
nosocomial infections, 80%, as stated by another study from Egypt [23].
The bacterial isolates are considered to exhibit MDR when the 
insensitivity is exposed to three or more antibiotics [5]. The percentage 
of MDR from the present study is somewhat high, almost 36% among 
95 bacterial isolates. However, many previous studies reported a 
higher percentage of MDR of Pseudomonas. The most recent one, 
conducted in Rajasthan, India, has reported that the incidence of MDR 
is 85.45% [3]. Some other studies worldwide also reveal high level 
of MDR of P. aeruginosa. Prior use of antibiotics, mainly carbapenem 
and fluoroquinolone, is considered as the major risk factor for 
the development of MDRPA. Besides, MDR may also occur by both 
acquisitions of drug resistance: By existing strains and by cross-
infection with resistant strains [9].
The present study showed that MDRPA bacteria were mostly derived 
from pus (13 out of 95 isolates). A recent study conducted in India also 
reported that P. aeruginosa is one of the most common Gram-negative 
bacteria obtained in the pus. Furthermore, the bacteria are resistant to 
third-generation cephalosporin such as ceftriaxone, ceftazidime, and 
cefotaxime [18].
The variation in the percentage of P. aeruginosa that is resistant 
to antibiotics among places and countries may be due to different 
level of irrational use of antibiotics. Irrational use of antibiotics in 
the community is a major cause of rising antibiotic resistance. This 
includes self-medication with antibiotics and poor adherence to 
dosage regimens [24]. Other factors such as commercial interests and 
a lack of knowledge about the rational use of antibiotics and antibiotic 
resistance were also proposed [25]. Early detection will greatly assist in 
the control of hospital infections caused by these bacteria [21].
CONCLUSION
The highest percentage of resistance from 95 clinical sample isolates of 
P. aeruginosa is to ceftriaxone (43.16%), whereas the least resistance is 
shown to amikacin (9.47%). MDRPA is counted 35.79%, mostly found 
in pus sample.
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